News

An independent review board has given a green light to Anthera Pharmaceuticals continuing a Phase 3 clinical trial evaluating Sollpura’s (lipromatase’s) ability to treat a cystic fibrosis-related digestive disorder. It was the second time that the Data Monitoring Committee had decided that interim findings were good enough for the…

Hill-Rom, which produces the Monarch Airway Clearance System for patients with cystic fibrosis (CF) and other diseases, has put its product on a “temporary shipping hold” as it scrambles to affix labels to 60 of the devices. According to a Class 2 recall notice posted by…

AIT Therapeutics’ nitric oxide mist led to a 65 percent reduction in cystic fibrosis patients’ airway bacteria and an improvement in their exercise capability 60 days after treatment, a Phase 2 clinical trial shows. The bacteria that the nitric oxide countered was the Mycobacterium abscessus complex. The exercise-capability yardstick researchers…

Changes in bacteria present in the lower respiratory tract during the first years of life may be indicative of early progression of lung disease in cystic fibrosis (CF) patients, according to researchers at the University of North Carolina School of Medicine. The finding was reported in the study, “…

A therapy whose developers say could revolutionize the battle against antibiotic-resistant lung infections in cystic fibrosis patients eliminated resistant Staphylococcus aureus in a lab, a study reports. The finding dealt with Synspira’s polycationic glycopolymer SNSP113 as a stand-alone treatment. The study also showed that the therapy increased the punch of antibiotics used to counter…

Dr. Beth A. Smith with the University at Buffalo has received a mental healthcare award from the Cystic Fibrosis Foundation for her work in advancing the understanding and care of mental health in cystic fibrosis — regarding both the prevalence of depression among patients and its impact on…

Motif Bio has received a $120,000 award from the Cystic Fibrosis Foundation (CFF) to fund in vitro testing of iclaprim — a broad-spectrum antibiotic — for the treatment of lung infections in people with cystic fibrosis (CF). Iclaprim is an antibiotic with potent in vitro activity against Gram-positive…

It takes only slightly longer to deliver an inhaled therapy in cystic fibrosis (CF) patients sitting upright than when lying alternately on either side, according to an Australian study. Usually, doctors have patients sit upright when inhaling nebulized medications in order to maximize the lung’s volume. However, experts say distribution patterns…

A study in young children with cystic fibrosis (CF) shows that low chest radiograph scores are associated with more frequent pulmonary exacerbations, and the use of antibiotics is beneficial when respiratory symptoms increase. Although it’s been established that pulmonary exacerbations lead to a decline in lung function in older children and…

Using a cystic fibrosis patient’s tissue to grow mini-guts in a lab has become easier and is   available to more scientists who want to use it both to study the disease and test patients’ response to therapies. Stemcell Technologies, a Canadian biotechnology company, has released two new lines…